Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Med J Aust ; 198(1): 27-8, 2013 Jan 21.
Artículo en Inglés | MEDLINE | ID: mdl-23330766

RESUMEN

Atrial fibrillation (AF) is estimated to affect 1%-2% of the population. It is increasing in prevalence and is associated with excess mortality, considerable morbidity and hospitalisations. AF is responsible for a significant and growing societal financial burden. Catheter ablation is an increasingly used therapeutic strategy for the management of AF; however, some confusion exists among those caring for patients with this condition about the role and optimal use of ablative treatments for AF. Our aim in this consensus statement is to provide recommendations on the use of primary catheter ablation for AF in Australia, on the basis of current evidence. Our consensus is that the primary indication for catheter ablation of AF is the presence of symptomatic AF that is refractory or intolerant to at least one Class 1 or Class 3 antiarrhythmic medication. In selecting patients for catheter ablation of AF, consideration should be given to the patient's age, duration of AF, left atrial size and the presence of significant structural heart disease. Best results are obtained in younger patients with paroxysmal AF, no structural heart disease and smaller atria. Ablation techniques for patients with persistent AF are still undergoing evaluation. Discontinuation of warfarin or equivalent therapies is not considered a sole indication for this procedure. After AF ablation, anticoagulation therapy is generally recommended for all patients for at least 1-3 months. Discontinuation of warfarin or equivalent therapies after ablation is generally not recommended in patients who have a CHADS 2 score (congestive heart failure, hypertension, age ≥ 75 years, diabetes, 1 point each; prior stroke or transient ischaemic attack, 2 points) of ≥ 2.


Asunto(s)
Fibrilación Atrial/terapia , Ablación por Catéter , Antiarrítmicos , Fibrilación Atrial/tratamiento farmacológico , Australia , Ablación por Catéter/efectos adversos , Ablación por Catéter/instrumentación , Ablación por Catéter/métodos , Humanos , Prevención Secundaria , Sociedades Médicas , Tromboembolia/etiología , Tromboembolia/prevención & control , Resultado del Tratamiento
2.
Med J Aust ; 198(9): 483-4, 2013 May 20.
Artículo en Inglés | MEDLINE | ID: mdl-23682890

RESUMEN

In 2003, the National Heart Foundation of Australia position statement on "stress" and heart disease found that depression was an important risk factor for coronary heart disease (CHD). This 2013 statement updates the evidence on depression (mild, moderate and severe) in patients with CHD, and provides guidance for health professionals on screening and treatment for depression in patients with CHD. The prevalence of depression is high in patients with CHD and it has a significant impact on the patient's quality of life and adherence to therapy, and an independent effect on prognosis. Rates of major depressive disorder of around 15% have been reported in patients after myocardial infarction or coronary artery bypass grafting. To provide the best possible care, it is important to recognise depression in patients with CHD. Routine screening for depression in all patients with CHD is indicated at first presentation, and again at the next follow-up appointment. A follow-up screen should occur 2-3 months after a CHD event. Screening should then be considered on a yearly basis, as for any other major risk factor for CHD. A simple tool for initial screening, such as the Patient Health Questionnaire-2 (PHQ-2) or the short-form Cardiac Depression Scale (CDS), can be incorporated into usual clinical practice with minimum interference, and may increase uptake of screening. Patients with positive screening results may need further evaluation. Appropriate treatment should be commenced, and the patient monitored. If screening is followed by comprehensive care, depression outcomes are likely to be improved. Patients with CHD and depression respond to cognitive behaviour therapy, collaborative care, exercise and some drug therapies in a similar way to the general population. However, tricyclic antidepressant drugs may worsen CHD outcomes and should be avoided. Coordination of care between health care providers is essential for optimal outcomes for patients. The benefits of treating depression include improved quality of life, improved adherence to other therapies and, potentially, improved CHD outcomes.


Asunto(s)
Enfermedad Coronaria/complicaciones , Enfermedad Coronaria/psicología , Depresión/diagnóstico , Depresión/terapia , Australia/epidemiología , Comorbilidad , Depresión/etiología , Humanos , Tamizaje Masivo , Derivación y Consulta , Factores de Riesgo
3.
Med J Aust ; 199(3): 179-80, 2013 Aug 05.
Artículo en Inglés | MEDLINE | ID: mdl-23909539

RESUMEN

In 2003, the National Heart Foundation of Australia published a position statement on psychosocial risk factors and coronary heart disease (CHD). This consensus statement provides an updated review of the literature on psychosocial stressors, including chronic stressors (in particular, work stress), acute individual stressors and acute population stressors, to guide health professionals based on current evidence. It complements a separate updated statement on depression and CHD. Perceived chronic job strain and shift work are associated with a small absolute increased risk of developing CHD, but there is limited evidence regarding their effect on the prognosis of CHD. Evidence regarding a relationship between CHD and job (in)security, job satisfaction, working hours, effort-reward imbalance and job loss is inconclusive. Expert consensus is that workplace programs aimed at weight loss, exercise and other standard cardiovascular risk factors may have positive outcomes for these risk factors, but no evidence is available regarding the effect of such programs on the development of CHD. Social isolation after myocardial infarction (MI) is associated with an adverse prognosis. Expert consensus is that although measures to reduce social isolation are likely to produce positive psychosocial effects, it is unclear whether this would also improve CHD outcomes. Acute emotional stress may trigger MI or takotsubo ("stress") cardiomyopathy, but the absolute increase in transient risk from an individual stressor is low. Psychosocial stressors have an impact on CHD, but clinical significance and prevention require further study. Awareness of the potential for increased cardiovascular risk among populations exposed to natural disasters and other conditions of extreme stress may be useful for emergency services response planning. Wider public access to defibrillators should be available where large populations gather, such as sporting venues and airports, and as part of the response to natural and other disasters.


Asunto(s)
Enfermedad Coronaria/epidemiología , Enfermedad Coronaria/psicología , Guías de Práctica Clínica como Asunto , Estrés Psicológico/epidemiología , Lugar de Trabajo/psicología , Adulto , Distribución por Edad , Australia/epidemiología , Consenso , Enfermedad Coronaria/fisiopatología , Depresión/epidemiología , Depresión/fisiopatología , Medicina Basada en la Evidencia , Femenino , Humanos , Incidencia , Masculino , Persona de Mediana Edad , Ocupaciones , Psicología , Factores de Riesgo , Índice de Severidad de la Enfermedad , Distribución por Sexo , Sociedades Médicas/normas , Estrés Psicológico/fisiopatología , Tolerancia al Trabajo Programado , Adulto Joven
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda